RecruitingPhase 2
Assessment of the Initial Efficacy and Safety of BRM424 Ophthalmic Solutions in Patients With Neurotrophic Keratitis
BRIM Biotechnology Inc. · NCT05927428
View Study & Apply (opens in a new tab)
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18+ · All sexes
- Healthy volunteers
- Not accepted (a condition is required)
- Study type
- Interventional · Phase 2
- Target enrollment
- 12
- US sites recruiting
- 1
- Study start
- July 31, 2024
- Record last updated
- October 28, 2024
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The objective of this study is to obtain initial efficacy of BRM424 in patients with Stage 2 and Stage 3 NK and evaluate safety and tolerability.
Being studied: BRM424 Ophthalmic Solution - Dose1; BRM424 Ophthalmic Solution - Dose2
Conditions: Neurotrophic Keratitis
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Be at least 18 years of age;
- Provide written informed consent;
- Patients with NK Stage 2 (PED) or Stage 3 (corneal ulcer);
Exclusion Criteria
- Any active ocular infection (bacterial, viral, fungal or protozoal) or active ocular inflammation not related to NK;
- Anticipated need to use therapeutic contact lenses or contact lens wear for refractive correction during the 28-days Treatment Period in the eye(s) with NK;
- Be a woman of childbearing potential who is not using an acceptable means of birth control;
Recruiting US locations
Wilmington Eye
Leland, NC 28451
Site contact: Crystal Wong · 910-763-3601 · cwong@wilmingtoneye.co